You're using an older browser that may not provide the best experience on our site - for optimal performance and security, please update your browser.
Past performance is not indicative of future results. The value of fund units/shares can rise as well as fall and you may not get back the amount you invested. Funds with a risk level of 5-7 according to the fund’s key information document (KID) can both decrease and increase significantly in value. Fund information, including the KID, prospectus, and sustainability-related disclosures can be found at Our Luxembourg funds.
This notice concerns investors in SEB Concept Biotechnology, which will merge into SEB Läkemedelsfond on 8 September 2025. Investors in SEB Läkemedelsfond are not affected.
Please note that the merger may have tax implications for German investors. Under the German Investment Tax Act (InvTA), tax-neutral treatment is only applicable when both the merging and receiving funds are domiciled in the same country. In this case, SEB Concept Biotechnology is domiciled in Luxembourg and SEB Läkemedelsfond is domiciled in Sweden. As a result, the merger is not considered tax-neutral under German tax law.
We recommend that you consult a financial adviser to evaluate how the merger may affect your personal tax situation. This notice is for information purposes only and does not constitute tax or financial advice. Individual circumstances may vary.